Agentic AI Poised to Generate $450B in Pharma Marketing Value by 2028

Transformative Power in Healthcare: Agentic AI

A new research report published by tech giant Google Cloud reveals that the healthcare and biotechnology industry is on the brink of a revolution that will reshape its marketing dynamics. This next-generation technology, called 'Agentic AI' or autonomous artificial intelligence systems, has the potential to create $450 billion in global marketing value by 2028. This figure is the clearest indicator of how effective AI will be not only in diagnosis and treatment but also in the way the industry conducts business.

A Radical Shift in Marketing Efficiency

The focus of the research is the transformation of communication between pharmaceutical and biotechnology companies and healthcare professionals. While traditional marketing approaches offer content that appeals to broad audiences and is not personalized, Agentic AI systems can analyze each physician's area of expertise, focus of interest, research history, and preferences in real-time. In light of these analyses, every communication is made completely personalized, thus ensuring that information reaches the right person, at the right time, and in the most effective format.

This personalized approach promises striking increases in the return on investment (ROI) of marketing activities. The system, which minimizes resource waste, aims to multiply the interaction rate of targeted healthcare workers with new treatment methods, clinical trial results, or drug information. Google Cloud experts state that with the adoption of this technology, the efficiency derived from marketing budgets could reach unprecedented levels within the next few years.

Global Investments and Turkey's Position

Artificial intelligence and biotechnology are among the areas that attract the most interest from global investors. According to information obtained from web sources, in 2024 alone, 469 deals were made in these fields, with investments exceeding $1.1 billion. These figures are indicative of the sector's growth speed and potential. It is known that Turkey has also designated biotechnology and artificial intelligence as priority areas within the scope of its 2030 industry and technology strategy. In this direction, the adoption of innovative solutions like Agentic AI by local companies and research centers is critical for the country's competitive strength in the global health technologies ecosystem.

Patient-Centered Outcomes and System Quality

The impact of Agentic AI is not limited to marketing efficiency. The system ultimately aims to contribute to better patient outcomes. By enabling physicians to quickly access the most current and most meaningful clinical data for them, it supports decision-making processes. This situation can directly contribute to raising healthcare quality and patient safety standards. As healthcare quality assessments and accreditation processes become increasingly data-driven and technology-focused, AI-supported systems are poised to become an integral part of these processes.

On the other hand, this transformation also brings some challenges. Data privacy, security, and ethical use are at the forefront of issues that require meticulous attention. A balanced model needs to be developed that optimizes information flow without harming the essence of the physician-patient relationship. Furthermore, comprehensive training programs will be needed for healthcare workers to adapt to these new technologies.

Future Scenarios and the Sector's Course

Google Cloud's projections foresee that Agentic AI will be decisive in the following areas in the near term:

• Smart Drug Promotion: Personalized information flow to physicians via virtual assistants.
• Clinical Trial Management: Much faster and more efficient identification of suitable patient populations and researchers.
• Education and Development: Continuous, customized training modules for healthcare professionals on new products and protocols.